Track topics on Twitter Track topics that are important to you
Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced breast cancer after hormonal therapy. The Scottish Medicines Consortium (SMC) said Ibrance – a CDK4/6 inhibitor – can increase the time befor...
Original Article: Scotland backs Pfizer’s Ibrance for breast cancerNEXT ARTICLE
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...